Introduction: Chemoresistance in breast cancer remains a major obstacle that limits the effectiveness of current therapeutic options for patients. Therefore, the identification or development of adjuvant compounds with minimal side effects to enhance the efficacy of standard treatments continues to be an important goal...
Vahid Mahmoudzadeh, Mehran Molavand, Azita Asadi et al.· Advanced Pharmaceutical Bull...· 0 citations
This mini-review synthesizes recent evidence on lncRNAs targeting the PI3K/AKT/mTOR cascade in breast cancer, summarizing molecular mechanisms, functional consequences for proliferation, invasion, and therapy resistance, and available in vitro and in vivo evidence.
Azita Asadi, Mehran Molavand, B. Yousefi· Mini-Reviews in Medical Chem...· 0 citations
Cancer is among the leading causes of global mortality. In addition to uncontrolled proliferation, cancer cells activate survival pathways that favor the expansion of malignant cell populations. A critical component of these survival mechanisms is drug resistance, which often prevents the achievement of optimal therape...
Mehran Molavand, Amir Valizadeh, M. Majidinia et al.· Advanced Pharmaceutical Bull...· 0 citations
Linarin demonstrates the capacity to potentiate 5-FU cytotoxicity by reactivating the p53/p21 pathway in CRC models harboring functional p53 by reactivating the p53/p21 pathway in linarin's sensitizing action in p53-competent cells.
Amir Valizadeh, M. Rahmati-Yamchi, A. Alihemmati et al.· Advanced Pharmaceutical Bull...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
